Xella Health, a San Francisco-based women’s precision health company, has raised $3.7 million in pre-seed funding. The round was led by Precursor Ventures with participation from Capital F, Ulu Ventures, and angel investors.
The company is developing multi-omic diagnostics that analyze menstrual fluid alongside peripheral blood to provide insights across fertility, hormonal health, perimenopause, and early cancer detection. Xella plans to launch in Spring 2026 and says it has nearly 10,000 people on its waitlist.
“Our mission is to give women the answers and care they have always deserved,” said Kelly Lacob, Co-Founder and CEO of Xella. “Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today. Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyze translates into meaningful, actionable health outcomes rather than more noise.”
The company’s testing uses at-home sample collection, including menstrual fluid swabs and blood draws, with results delivered through a digital health portal. Users receive personalized treatment plans and ongoing clinician support.
Pricing will start at $449 for a standard membership, with a $949 premium tier for active condition management and $249 for quarterly hormone monitoring. Insurance coverage is planned for the future.
“Xella is rethinking women’s health from the ground up—starting with the insight women need to make sense of their own biology over time,” said Ashtan Jordan, Principal at Precursor Ventures. “The team is building with a rare combination of scientific depth, product intuition, and empathy for the lived realities of women, which is exactly what’s required to create a trusted, enduring platform in healthcare.”
Xella was co-founded by Lacob, formerly of Mammoth Biosciences, alongside Adriana Dantas (COO), who previously held roles at Roche and BD, and Jesus Ching, PhD (CTO), formerly of Mammoth Biosciences and Arc Bio.
